Medmare Bt.

Veszprem 14 trials 4 recruiting

14 Registered trials

4 Currently recruiting

Organisation

Medmare Bt.

Location

Veszprem, Hungary

Identifier

ORG-100042957

Address

Jozsef Attila Utca 17, 8200, Hungary

Departments

Dermatology Department
Medmare Bt.
N/A
NA

Clinical trials at this site (14)

Search interface

Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505120-59-00 Moderate to Severe Plaque Psoriasis 5 2023-12-19
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended

2024-512207-39-00 Plaque Psoriasis 4 2025-01-30
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera… Ended

2023-505433-27-00 Atopic Dermatitis 5 2024-08-13
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Ended

2022-502888-38-00 Atopic dermatitis 4 2023-09-25
A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis Ended

2022-502249-90-00 Plaque Psoriasis 4 2023-08-31
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15